A LinkedIn post from Cymbiotika highlights the introduction of a new product, Liposomal NAD+, positioned as the company’s most advanced launch to date. The post describes the supplement as targeting longevity and healthy aging at the cellular level, with a formulation featuring 300 mg of NAD+ and 1000 mg of TMG, and emphasizes claims of up to three times higher absorption via advanced liposomal delivery.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Cymbiotika is deepening its focus on the premium longevity and wellness segment, which could support higher average selling prices and margin expansion if consumer demand materializes. By showcasing innovation and naming multiple team members involved, the post may signal continued investment in product development and brand differentiation, potentially strengthening the company’s competitive position in the nutraceutical and wellness market.